MedKoo product information:

 Doxifluridine

Doxifluridine is a fluoropyrimidine derivative and oral prodrug of the antineoplastic agent 5-fluorouracil (5-FU) with antitumor activity. Doxifluridine, designed to circumvent the rapid degradation of 5-FU by dihydropyrimidine dehydrogenase in the gut wall, is converted into 5-FU in the presence of pyrimidine nucleoside phosphorylase. 5-FU interferes with DNA synthesis and subsequent cell division by reducing normal thymidine production and interferes with RNA transcription by competing with uridine triphosphate for incorporation into the RNA strand. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). 

  1: Nakayama T, Noguchi S. Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan. Oncologist. 2010;15(1):26-36. Epub 2010 Jan 15. Review. PubMed PMID: 20080863.

2: Huh JW, Kim HR. Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0? J Surg Oncol. 2009 Oct 1;100(5):387-91. PubMed PMID: 19582821.

3: Park JM, Kim YH. Current approaches to gastric cancer in Korea. Gastrointest Cancer Res. 2008 May;2(3):137-44. PubMed PMID: 19259291; PubMed Central PMCID: PMC2633072.

4: Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009 Mar;18(3):335-48. Review. PubMed PMID: 19243284.

5: Sugae T, Yaguchi T, Kajikawa M, Nakayama S, Takase T, Inokawa Y, Tsushima Y, Watanabe T, Harada A. [A case report of primary adenocarcinoma of small intestine successfully treated with FOLFOX]. Gan To Kagaku Ryoho. 2008 Nov;35(11):1969-71. Japanese. PubMed PMID: 19011354.

6: Honma H. [Successful treatment of an elderly patient with pretreated recurrent breast cancer using low-dose capecitabine]. Gan To Kagaku Ryoho. 2006 Dec;33(13):2045-8. Japanese. PubMed PMID: 17197750.

7: Yamane M, Mizuta M, Kaji M, Toyokawa T, Miyatani K, Udaka T, Kubo M, Hosokawa N, Suwaki K, Shirakawa K. [Effectiveness of preoperative chemoradiotherapy for advanced rectal cancer]. Gan To Kagaku Ryoho. 2006 Oct;33(10):1441-4. Japanese. PubMed PMID: 17033234.

8: Chugoku-Shikoku Breast Cancer Chemotherapy Study Group, Ikeda M, Sonoo H, Tanaka K, Kurebayashi J, Morimoto T, Tangoku A, Komaki K, Kataoka T, Ishiguro K, Yoshizawa K. [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study]. Gan To Kagaku Ryoho. 2006 Jun;33(6):767-71. Japanese. PubMed PMID: 16770094.

9: Minami H, Ebi H. [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)]. Gan To Kagaku Ryoho. 2005 Dec;32(13):2053-7. Japanese. PubMed PMID: 16352928.

10: Sawada N, Nose T, Ishikawa T, Yutaka T. Enhancement of antitumor activity of 5'-deoxy-5-fluorouridine (Furtulon) by taxane in human gastric cancer xenografts. Oncol Rep. 2005 Jul;14(1):53-7. PubMed PMID: 15944767.

11: Emi Y, Kakeji Y, Baba H, Ishida T, Maehara Y. [Current combination chemotherapy containing paclitaxel for advanced, recurrent gastric cancer]. Gan To Kagaku Ryoho. 2004 Nov;31(12):1978-81. Review. Japanese. PubMed PMID: 15570924.

12: Saeki T, Takashima S. Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer. Breast Cancer. 2004;11(2):116-20. Review. PubMed PMID: 15550855.

13: Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004 May 19;96(10):739-49. PubMed PMID: 15150302.

14: Jin A, Qi Y, Mori E, Guo M, Takasaki S, Mori T. Therapeutic effects of novel anti-tumor reagent, apoptosis inducing nucleosides from CD57+HLA-DRbright natural suppressor cell line on human gastric carcinoma-bearing SCID mice. Int J Oncol. 2004 Jun;24(6):1523-8. PubMed PMID: 15138596.

15: Schöffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs. 2004 Feb;15(2):85-106. Review. PubMed PMID: 15075664.

16: Sato A, Ito T, Tomita T, Nakamura A, Taguchi S. [Chemotherapy of gastric cancer--a review of clinical trials in Japan]. Gan To Kagaku Ryoho. 2002 Sep;29(9):1522-31. Review. Japanese. PubMed PMID: 12355938.

17: Tominaga T, Toi M, Ohashi Y, Abe O; 5'-BC Study Group. Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients. Clin Breast Cancer. 2002 Apr;3(1):55-64. PubMed PMID: 12020396.

18: Iba T, Kidokoro A, Fukunaga M, Sugiyama K, Aihara N, Suda M. [The efficacy of combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR), cyclophosphamide (CPA) and medroxyprogesterone acetate (MPA) for bone metastasis in breast cancer patients]. Gan To Kagaku Ryoho. 2001 Jul;28(7):973-7. Japanese. PubMed PMID: 11478147.

19: Kim NK, Min JS, Park JK, Yun SH, Sung JS, Jung HC, Roh JK. Intravenous 5-fluorouracil versus oral doxifluridine as preoperative concurrent chemoradiation for locally advanced rectal cancer: prospective randomized trials. Jpn J Clin Oncol. 2001 Jan;31(1):25-9. PubMed PMID: 11256837.

20: Kubota Y, Noguchi S, Masuda M, Hosaka M, Noguchi K, Sasaki K, Miura T, Ikeda I, Kondo I, Senga Y, Moriyama M, Fukushima S, Ebato T, Fukuda M, Kitami K, Fukuoka H, Sato K, Hirokawa M, Chiba K, Kanno H, Miyai K. [5'-DFUR chemoprophylaxis in superficial bladder cancer. Kanagawa Urology 5'-DFUR Study Group]. Hinyokika Kiyo. 2000 Aug;46(8):525-30. Japanese. PubMed PMID: 11019370.

21: Di Costanzo F, Sdrobolini A, Gasperoni S. Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2000 Aug;35(2):101-8. Review. PubMed PMID: 10936467.

22: Takahashi Y, Mai M, Taguchi T, Urushizaki I, Nishioka K. Prolonged stable disease effects survival in patients with solid gastric tumor: analysis of phase II studies of doxifluridine. Int J Oncol. 2000 Aug;17(2):285-9. PubMed PMID: 10891537.

23: Takeuchi I, Ishida H, Suzuki T, Nakada H, Yamada H, Idezuki Y, Hohya I. [A case of diffusely infiltrating carcinoma of the sigmoid colon associated with lymphangitis carcinomatosa effectively treated with sequential MTX.5-FU and 5'-DFUR]. Gan To Kagaku Ryoho. 2000 Feb;27(2):289-93. Japanese. PubMed PMID: 10700903.

24: Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer. 1999 Sep 24;83(1):127-34. PubMed PMID: 10449619.

25: Zampino MG, Colleoni M, Bajetta E, Stampino CG, Guenzi A, de Braud F. Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. Tumori. 1999 Jan-Feb;85(1):47-50. PubMed PMID: 10228497.

26: Del Vecchio M, Procopio G, Cassata A, Pozzi P, Busto G, Celio L, Bajetta E. Fluoropyrimidines in the treatment of advanced neoplastic diseases: role and advantages of UFT. Tumori. 1999 Jan-Feb;85(1):6-11. Review. PubMed PMID: 10228489.

27: González Barón M. [Oral fluoropyrimidines in oncology]. An R Acad Nac Med (Madr). 1998;115(3):721-45; discussion 745-6. Review. Spanish. PubMed PMID: 10208021.

28: Tominaga T. [Recent development of oral anti-cancer drugs for breast cancer]. Gan To Kagaku Ryoho. 1999 Feb;26(3):301-7. Review. Japanese. PubMed PMID: 10065092.

29: Taguchi T. [Gastrointestinal cancer and oral anticancer agents]. Gan To Kagaku Ryoho. 1999 Feb;26(3):284-94. Review. Japanese. PubMed PMID: 10065090.

30: Bajetta E, Buzzoni R, Artale S, Di Bartolomeo M. Doxifluridine: previous experience and new developments in the treatment of colorectal cancer. Tumori. 1997 Jan-Feb;83(1 Suppl):S87-9. PubMed PMID: 9154079.

31: Baldini E, Tibaldi C, Pfanner E, Ricci S, Falcone A, Ceribelli A, Sarcina R, Comella G, Stampino CG, Conte PF. Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer. Am J Clin Oncol. 1996 Dec;19(6):592-4. PubMed PMID: 8931679.

32: Iwagaki H, Hizuta A, Fujiwara T, Perdomo JA, Tanaka N, Orita K. Effect of low dose cyclophosphamide on the synthesis of acute phase protein and its significance for cancer chemotherapy. Acta Med Okayama. 1996 Oct;50(5):271-2. PubMed PMID: 8914681.

33: Agata N, Mase T, Izumi H, Hirano S, Iguchi H, Tone H, Takeuchi T. Antitumor effects of pirarubicin and epirubicin in combination with doxifluridine and cisplatin against mouse P388 leukemia. Cancer Biochem Biophys. 1995 Nov;15(2):95-101. PubMed PMID: 8590441.

34: Nakata E, Okajima K, Ishida Y, Munetomo Y, Gotoh K, Toyohara M, Miyazaki H, Matsunaga S, Maeura Y, Fujimura T, et al. [Combination therapy of high dose 5'-DFUR+MMC for advanced or recurrent gastric cancer. 5'-DFUR Joint Research Group in the Osaka District for Gastric Cancer]. Gan To Kagaku Ryoho. 1995 Oct;22(12):1799-806. Japanese. PubMed PMID: 7574813.

35: Colleoni M, Nelli P, Manente P. Clinical development of new fluoropyrimidines: a major improvement in colorectal cancer treatment? Tumori. 1995 Sep-Oct;81(5):303-7. Review. PubMed PMID: 8804444.

36: Di Bartolomeo M, Bajetta E, Somma L, Buzzoni R. Doxifluridine: an active agent in advanced gastrointestinal cancer. Tumori. 1995 May-Jun;81(3 Suppl):147-50. PubMed PMID: 7571047.

37: Kurihara M. [Process of making a protocol for advanced gastric cancer chemotherapy--using 5'-DFUR+CDDP as an example]. Gan To Kagaku Ryoho. 1993 Dec;20(16):2447-53. Review. Japanese. PubMed PMID: 8279840.

38: Antimi M, Majoli L, Minelli M, Stampino CG, Pandolfi A, Papa G. A phase I safety study of doxifluridine and interferon-alpha-2a in patients with advanced neoplastic disease. Tumori. 1993 Oct 31;79(5):336-9. PubMed PMID: 8116077.

39: Urushizaki I. [Chemotherapy for older cancer patients]. Gan To Kagaku Ryoho. 1993 May;20(7):850-7. Japanese. PubMed PMID: 7683866.

40: Kamata R, Saito T, Yamashita T, Sekiguchi K, Shibuya H, Horiuchi J, Ebata K, Sanuki E, Endo M, Sato K, et al. [Multi-institutional trials of radiation and Furtulon combination therapy for malignant tumors]. Gan To Kagaku Ryoho. 1992 May;19(5):665-70. Japanese. PubMed PMID: 1533756.

41: Winkelmann JJ, Alberto P, Mermillod B. [Doxifluridine toxicity, a fluorouracil analog with low myelosuppressive effect]. Bull Cancer. 1990;77(3):225-34. French. PubMed PMID: 2140280.

42: Tamura Y, Sakata Y, Ogasawara H, Itoh T, Furukohri N, Saitoh S, Tsushima K, Baba T, Munakata A, Yoshida Y. [Two cases of gastrointestinal cancers with major responses to sequential methotrexate 5-FU plus 5'-DFUR]. Gan To Kagaku Ryoho. 1989 May;16(5):2109-12. Japanese. PubMed PMID: 2525005.

43: Tsukagoshi S. [Problems in the development of analogs of anticancer drugs]. Gan To Kagaku Ryoho. 1988 Aug;15(8):2173-8. Japanese. PubMed PMID: 2457354.

44: Miwa M, Eda H, Fukuda H, Fujimoto K, Ishitsuka H. [Comparative studies on the antitumor activity of the fluorinated pyrimidines 5'-DFUR, tegafur, UFT and FUra on various murine tumors]. Gan To Kagaku Ryoho. 1988 May;15(5):1755-63. Japanese. PubMed PMID: 2967051.

45: Alberto P, Mermillod B, Germano G, Kaplan S, Weber W, Joss R, Spati B, Martz G, Cavalli F. A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. Eur J Cancer Clin Oncol. 1988 Mar;24(3):559-63. PubMed PMID: 2968263.

46: Lai KH, Tsai YT, Lee SD, Yeh YS, Wang SS, Ng WW, Wang JY, Chiang TT, Lay CS, Yang CF, et al. Clinical trial of doxifluridine in the treatment of primary hepatocellular carcinoma. Cancer Treat Rep. 1986 Nov;70(11):1339-40. PubMed PMID: 3021327.

47: Hurteloup P, Armand JP, Cappelaere P, Metz R, Kerbrat P, Keiling R, Fumoleau P, Fargeot P, Schraub S, Bastit P, et al. Phase II clinical evaluation of doxifluridine. Cancer Treat Rep. 1986 Jun;70(6):731-7. PubMed PMID: 2942245.

48: Hoshino A, Ohara K, Kamiya O, Nagata K, Ono Y, Kawakubo A, Ozaki Y, Suzuki A, Ogasawara T, Sugiura I, et al. [Clinical trial of a new fluorinated pyrimidine, 5'-deoxy-5-fluorouridine (5'-DFUR)]. Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 1):1079-82. Japanese. PubMed PMID: 2938548.

49: Irie K, Yasutake K, Imamura Y, Yoshimura Y, Yoshida M, Nakamura T, Suehiro I. [Clinical trial of 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced cancer patients]. Gan To Kagaku Ryoho. 1985 Dec;12(12):2371-8. Japanese. PubMed PMID: 2934026.

50: Okumura T. [Clinical trial of 5'-DFUR against various malignant tumors]. Gan To Kagaku Ryoho. 1985 Dec;12(12):2365-70. Japanese. PubMed PMID: 2934025.

51: Fujita F, Fujita M, Taguchi T. [Effects of 5'-deoxy-5-fluorouridine on human gastrointestinal and breast cancers xenografted to nude mice]. Gan To Kagaku Ryoho. 1984 Aug;11(8):1635-43. Japanese. PubMed PMID: 6236751.